Viking Therapeutics/$VKTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Ticker
$VKTX
Sector
Primary listing
Employees
49
Headquarters
Website
VKTX Metrics
BasicAdvanced
$3.9B
-
-$1.54
0.62
-
Price and volume
Market cap
$3.9B
Beta
0.62
52-week high
$74.15
52-week low
$18.92
Average daily volume
5.3M
Financial strength
Current ratio
25.86
Quick ratio
25.257
Long term debt to equity
0.052
Total debt to equity
0.11
Interest coverage (TTM)
-2,217.05%
Profitability
Management effectiveness
Return on assets (TTM)
-14.99%
Return on equity (TTM)
-19.99%
Valuation
Price to book
4.94
Price to tangible book (TTM)
4.94
Price to free cash flow (TTM)
-25.599
Free cash flow yield (TTM)
-3.91%
Free cash flow per share (TTM)
-1.366
Growth
Earnings per share change (TTM)
64.31%
3-year earnings per share growth (CAGR)
26.33%
10-year earnings per share growth (CAGR)
-4.36%
What the Analysts think about VKTX
Analyst ratings (Buy, Hold, Sell) for Viking Therapeutics stock.
Bulls say / Bears say
VK2735 achieved up to 12.2% body weight reduction over 13 weeks in a Phase 2 trial, putting it on par with other oral GLP-1 treatments and supporting its profile as an effective obesity drug (Reuters)
Pfizer’s decision to end danuglipron development has reduced competition in the oral GLP-1 sector, which could boost Viking’s chances once VK2735 is approved (Reuters)
The oral obesity drug market is projected to reach $150 billion, and the convenience of VK2735 as a once-daily pill could help it secure a strong market position compared to injectable drugs (Reuters)
VK2735 saw a 20% drop-out rate compared to 13% for placebo, mostly due to gastrointestinal side effects, which raises significant questions about how well patients will tolerate it in the real world (Reuters)
Viking’s stock fell nearly 35% in premarket trading after the mid-stage VK2735 data, reflecting investor concerns over the drug’s safety record and prospects for success (Reuters)
There is greater regulatory scrutiny on oral GLP-1 drugs, especially after Pfizer stopped developing danuglipron due to safety problems. This could mean stricter approval processes for VK2735, possible launch delays, and higher development costs (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
VKTX Financial Performance
Revenues and expenses
VKTX Earnings Performance
Company profitability
VKTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Viking Therapeutics stock?
Viking Therapeutics (VKTX) has a market cap of $3.9B as of October 11, 2025.
What is the P/E ratio for Viking Therapeutics stock?
The price to earnings (P/E) ratio for Viking Therapeutics (VKTX) stock is 0 as of October 11, 2025.
Does Viking Therapeutics stock pay dividends?
No, Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders as of October 11, 2025.
When is the next Viking Therapeutics dividend payment date?
Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Viking Therapeutics?
Viking Therapeutics (VKTX) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.